Technology Networks – Analytical Cannabis’ sister publication – spoke to the team at Delix Therapeutics' to learn how their drugs can keep the benefits of psychedelics compounds while leaving behind the trip.
The credibility watchdog praised Analytical Cannabis’ dedication to fact-based reporting of cannabis industry events and relevant scientific research.
While these psychedelics users did tend to report an increased belief in the paranormal after their trip, superstitious beliefs largely remained unchained.
The first-of-its-kind phase 3 trial will soon begin in the UK to test whether ketamine can help treat patients with alcohol use disorder.
Stephen Wright breaks down the lengthy process of getting a psychedelic medicine approved in the US.